Literature DB >> 2969284

Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

P Allavena1, P Lo Presti, M Di Bello, V Lucchini, A Lissoni, G Zanetta, C Mangioni, A Mantovani.   

Abstract

Peripheral blood lymphocytes (PBL) from 43 patients with histologically confirmed ovarian carcinoma were stimulated in mixed lymphocyte-tumor culture (MLTC) with purified autologous tumor cells. Positive results, assessed as lymphocyte proliferation, were observed in 21 cases (48.8%). Lymphoid cells associated with ascitic fluid or infiltrating solid masses were in general less reactive than PBL as only 3/11 cases had positive MLTC. Tumor cells isolated from peritoneal effusions showed no significant difference in stimulatory potential as compared to the primary tumor. These results suggest that in an appreciable proportion of ovarian carcinoma patients (approximately 50%), lymphocytes have the potential to react to autologous tumor cells. Comprehension of the immunological mechanisms of antitumor resistance may have direct practical relevance for more effective treatment of neoplasms.

Entities:  

Mesh:

Year:  1988        PMID: 2969284     DOI: 10.1007/bf00205761

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

Review 1.  Tumor-specific transplantation antigens: G. H. A. Clowes memorial lecture.

Authors:  G Klein
Journal:  Cancer Res       Date:  1968-04       Impact factor: 12.701

2.  Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.

Authors:  A Lichtenstein; J Berek; R Bast; C Spina; N Hacker; R C Knapp; J Zighelboim
Journal:  J Biol Response Mod       Date:  1984-08

3.  Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course. I. Evaluation of 46 patients with sarcoma.

Authors:  F Vánky; J Willems; A Kreicbergs; T Aparisi; M Andréen; L A Broström; U Nilsonne; E Klein; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans.

Authors:  B M Vose; F Vanky; E Klein
Journal:  Int J Cancer       Date:  1977-10-15       Impact factor: 7.396

5.  Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin.

Authors:  G Peri; N Polentarutti; C Sessa; C Mangioni; A Mantovani
Journal:  Int J Cancer       Date:  1981-08-15       Impact factor: 7.396

6.  Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells.

Authors:  S Ferrini; R Biassoni; A Moretta; M Bruzzone; A Nicolin; L Moretta
Journal:  Int J Cancer       Date:  1985-09-15       Impact factor: 7.396

Review 7.  Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

Authors:  L J Old
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

8.  The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.

Authors:  D Taramelli; G Fossati; A Balsari; R Marolda; G Parmiani
Journal:  Int J Cancer       Date:  1984-12-15       Impact factor: 7.396

9.  Quantitation of proliferative and cytotoxic precursor cells directed against human tumours: limiting dilution analysis in peripheral blood and at the tumour site.

Authors:  B M Vose
Journal:  Int J Cancer       Date:  1982-08-15       Impact factor: 7.396

10.  Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.

Authors:  F Cozzolino; M Torcia; A M Carossino; R Giordani; C Selli; G Talini; E Reali; A Novelli; V Pistoia; M Ferrarini
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

View more
  3 in total

1.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.

Authors:  M Apiranthitou-Drogari; C Paganin; S Bernasconi; G Losa; A Maneo; N Colombo; A Mantovani; P Allavena
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside.

Authors:  G Pawelec; H Schmidt; A Rehbein; F Busch
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.